BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11916502)

  • 21. Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
    Friedman HS; Kerby T; Fields S; Zilisch JE; Graden D; McLendon RE; Houghton PJ; Arbuck S; Cokgor I; Friedman AH
    Cancer; 1999 Mar; 85(5):1160-5. PubMed ID: 10091802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study.
    Jeremic B; Grujicic D; Jevremovic S; Stanisavljevic B; Milojevic L; Djuric L; Mijatovic L
    J Clin Oncol; 1992 Jul; 10(7):1074-7. PubMed ID: 1318951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study.
    Jeremic B; Shibamoto Y; Grujicic D; Stojanovic M; Milicic B; Nikolic N; Dagovic A; Aleksandrovic J
    J Neurooncol; 2001 Jan; 51(2):133-41. PubMed ID: 11386410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
    Warren K; Jakacki R; Widemann B; Aikin A; Libucha M; Packer R; Vezina G; Reaman G; Shaw D; Krailo M; Osborne C; Cehelsky J; Caldwell D; Stanwood J; Steinberg SM; Balis FM
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):343-7. PubMed ID: 16408203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma.
    Prados MD; Schold SC; Fine HA; Jaeckle K; Hochberg F; Mechtler L; Fetell MR; Phuphanich S; Feun L; Janus TJ; Ford K; Graney W
    Neuro Oncol; 2003 Apr; 5(2):96-103. PubMed ID: 12672281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
    Johnson DH; Paul DM; Hande KR; DeVore R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.
    Perez EA; Suman VJ; Rowland KM; Ingle JN; Salim M; Loprinzi CL; Flynn PJ; Mailliard JA; Kardinal CG; Krook JE; Thrower AR; Visscher DW; Jenkins RB
    Clin Breast Cancer; 2005 Dec; 6(5):425-32. PubMed ID: 16381626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.
    Raizer JJ; Grimm S; Chamberlain MC; Nicholas MK; Chandler JP; Muro K; Dubner S; Rademaker AW; Renfrow J; Bredel M
    Cancer; 2010 Nov; 116(22):5297-305. PubMed ID: 20665891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.
    Franceschi E; Cavallo G; Scopece L; Paioli A; Pession A; Magrini E; Conforti R; Palmerini E; Bartolini S; Rimondini S; Esposti RD; Crinò L
    Br J Cancer; 2004 Sep; 91(6):1038-44. PubMed ID: 15305187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: a phase II study of the Fox Chase Cancer Center and its network.
    Langer CJ; Millenson M; Rosvold E; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-81-S12-88. PubMed ID: 9331128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and progression in recurrent malignant glioma.
    Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
    Neuro Oncol; 1999 Oct; 1(4):282-8. PubMed ID: 11550320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
    Brandes AA; Ermani M; Turazzi S; Scelzi E; Berti F; Amistà P; Rotilio A; Licata C; Fiorentino MV
    J Clin Oncol; 1999 Feb; 17(2):645-50. PubMed ID: 10080610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
    Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.